Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BETAFECTIN EFFICACY TO BE EXAMINED v. SURGICAL SITE INFECTIONS

Executive Summary

BETAFECTIN EFFICACY TO BE EXAMINED v. SURGICAL SITE INFECTIONS in an upcoming Phase III trial of the beta glucan polymer under development by Alpha-Beta Technology. The Phase III trial will enroll 900 patients with major elective gastrointestinal surgery at 25 to 30 centers. Patients will be randomized to placebo, .5 mg/kg Betafectin, or 1 mg/kg Betafectin. Alpha-Beta projects that the study will begin by the end of calendar 1994.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS024492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel